114
S. B. Christensen et al.
PSMA-targeted nanoparticle developed in his laboratory have
been out-licensed and tested in Phase I-III clinical trials. As a
clinician scientist, Dr. Denmeade has been the Principal Investigator on a number of clinical trials with a particular focus on
hormonal therapy-based trials. Most recently he has completed
an innovative trial demonstrating that administration of a highdose testosterone could be safely given to men with castrationresistant prostate cancer while producing a significant therapeutic effect.
John T. Isaacs obtained a Ph.D. degree in Biochemistry in
1978 from Emory University, Atlanta, GA, under the direction
of Professor Francis Binkley. He did his postdoctoral fellowship training in Pharmacology and Experimental Therapeutics
with Professor Donald S. Coffey at the Johns Hopkins University School of Medicine (JHSOM) where he became a faculty
member in 1980. Since 1993, he has been a Full Professor
in three departments in the JHSOM (i.e. Urology. Oncology,
Pharmacology, and Molecular Sciences) and in the Chemical
and Molecular Engineering Department in the Johns Hopkins
University, Kreiger School of Arts and Science, Baltimore,
Maryland. He also is the past Director of the Cellular and
Molecular Medicine Graduate Program at JHSOM, Baltimore,
Maryland. He has served as a member of editorial boards on
seven journals in oncology, including being the Editor-in-Chief
of “The Prostate”. His long-term goal is to develop effective
therapies to decrease the death rates due to cancer, particularly
prostate cancer. This goal requires not only pre-clinical development and validation of specific approaches, but the translation of these basic science findings into clinical development
and human trials. In this regard, his group has an established
record of translating pre-clinical discoveries into clinical trials
(i.e., four drugs taken into clinical trials). Presently, a series
of agents that his group invented/developed are currently in
various phases of clinical testing. He has contributed to 325
peer-reviewed manuscripts, 17 patents, and 70 book chapters.
Throughout his career, he has received various awards
and honors, including from the Sigma Xi (Emory University Chapter) Most Outstanding Graduate Student Research,
CaPCure Foundation Competitive Awards, Past President of the
Society for Basic Urologic Research, the Life Achievement
Award from the Society for Basic Urologic Research, and the
Prostate Cancer Foundation Movember Challenge Award. He is
a member of the National Academy of Inventors (USA).
S. B. Christensen et al.
PSMA-targeted nanoparticle developed in his laboratory have
been out-licensed and tested in Phase I-III clinical trials. As a
clinician scientist, Dr. Denmeade has been the Principal Investigator on a number of clinical trials with a particular focus on
hormonal therapy-based trials. Most recently he has completed
an innovative trial demonstrating that administration of a highdose testosterone could be safely given to men with castrationresistant prostate cancer while producing a significant therapeutic effect.
John T. Isaacs obtained a Ph.D. degree in Biochemistry in
1978 from Emory University, Atlanta, GA, under the direction
of Professor Francis Binkley. He did his postdoctoral fellowship training in Pharmacology and Experimental Therapeutics
with Professor Donald S. Coffey at the Johns Hopkins University School of Medicine (JHSOM) where he became a faculty
member in 1980. Since 1993, he has been a Full Professor
in three departments in the JHSOM (i.e. Urology. Oncology,
Pharmacology, and Molecular Sciences) and in the Chemical
and Molecular Engineering Department in the Johns Hopkins
University, Kreiger School of Arts and Science, Baltimore,
Maryland. He also is the past Director of the Cellular and
Molecular Medicine Graduate Program at JHSOM, Baltimore,
Maryland. He has served as a member of editorial boards on
seven journals in oncology, including being the Editor-in-Chief
of “The Prostate”. His long-term goal is to develop effective
therapies to decrease the death rates due to cancer, particularly
prostate cancer. This goal requires not only pre-clinical development and validation of specific approaches, but the translation of these basic science findings into clinical development
and human trials. In this regard, his group has an established
record of translating pre-clinical discoveries into clinical trials
(i.e., four drugs taken into clinical trials). Presently, a series
of agents that his group invented/developed are currently in
various phases of clinical testing. He has contributed to 325
peer-reviewed manuscripts, 17 patents, and 70 book chapters.
Throughout his career, he has received various awards
and honors, including from the Sigma Xi (Emory University Chapter) Most Outstanding Graduate Student Research,
CaPCure Foundation Competitive Awards, Past President of the
Society for Basic Urologic Research, the Life Achievement
Award from the Society for Basic Urologic Research, and the
Prostate Cancer Foundation Movember Challenge Award. He is
a member of the National Academy of Inventors (USA).